CellEDIT - CRISPR-Edited KPC Cell Line
Let us support you with a custom and high-quality engineered KPC cell line.
We’ll handle the CRISPR editing of your KPC cells, so you can focus on your research.
KPC cell lines are the gold standard for research into pancreatic ductal adenocarcinoma (PDA), the most common form of pancreatic cancer (95%). The KPC cell line was derived from a genetically engineered mouse model of pancreatic ductal adenocarcinoma. There are several types of cell lines belonging to this class, each with different mutations in the K-ras gene and Pdx1-Cre (KC lines), an additional mutation in p53 (KPC lines) and in Rosa26 YFP/YFP gene (KPCY lines).
KPC Cell Line Information
Organism
Mouse
Tissue Type
Pancreas
Cell Type
Pancreatic
Disease
Adenocarcinoma
Donor Information
Gender
Male
KPC Cell Line Applications
Cancer Research: KPC cells are a primary model for studying the biology of pancreatic ductal adenocarcinoma, including tumor growth, metastasis, and the molecular mechanisms driving pancreatic cancer progression.
Drug Screening and Development: These cells are used to test the efficacy and toxicity of potential therapeutic compounds targeting pancreatic cancer, aiding in the development of new treatments.
Tumor Microenvironment Studies: Researchers use KPC cells to investigate the interactions between pancreatic cancer cells and their surrounding microenvironment, which is crucial for understanding cancer progression and resistance to therapy.
Genetic and Molecular Pathway Analysis: The KPC cell line is employed to study the genetic mutations and molecular pathways involved in pancreatic cancer, particularly the roles of the Kras and Trp53 mutations, which are central to PDA development.
Immunotherapy Research: KPC cells are used in studies exploring the immune response to pancreatic cancer and the development of immunotherapies, including checkpoint inhibitors and other immune-modulating treatments.
Related Case Studies
Maximize your research capabilities with the help of CellEDIT. Custom engineered KPC cell lines are an invaluable tool in advancing our understanding of pancreatic cancer and developing effective treatments. With the CellEDIT workflow and within 10 weeks, we can support you with custom and monoclonal knockout KPC cell lines suited for your project needs.
Efficient on
Hard-to-transfect cells
Vector-free
direct intra-nuclear delivery
Minimized Off-Target
Immortalized Cells
Learn how the CellEDIT workflow was used to generate 5 monoclonal HPRT knockouts in C2C12 cell line through direct intra-nuclear injection of only 51 cells.
Hard-to-Transfect Cells
Discover how
the CellEDIT workflow was used to produce 3 monoclonal HPRT1 knockouts in SK-MES-1 cell, a notoriously hard-to-transfect cell line.
Available Edits using CellEDIT Engineered Cells
Knockout
Save time in the lab by empowering your research with CellEDIT. Confidently streamline your drug discovery workflow and investigate gene function with effective CRISPR knockouts.
Multiplex Editing
At CellEDIT, we provide you with multiplexed cell lines in 10 weeks. The efficiency and gentleness of our vector-free editing through intra-nuclear delivery, makes it an ideal system to perform multiplex gene editing in one go.
Related Resources
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
An Overview of CellEDIT' CRISPR Cell Line Development Services
CellEDIT' CRISPR Cell Line Development Workflow
CellEDIT's Engineered Cell Lines
CRISPR-Engineered U2OS Cell Line
CRISPR-Engineered MDA MB 231 Cell Line
CRISPR-Engineered A549 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.